Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.57 |
| ▸ | HTR3B | O95264 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28823824 | 0.98 | ALDH1A1 (0.63) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| Tert-Butyl Formate SCHEMBL27908417 | 0.88 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| SCHEMBL27821389 | 0.87 | ALDH1A1 (0.54) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL6132228 | 0.87 | ALDH1A1 (0.51) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| SCHEMBL20897465 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHRHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL2951325 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHRHSD17B10USP2MAPT | |
| SCHEMBL5742108 | 0.83 | ALDH1A1 (0.69) | ALDH1A1TSHRHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL62795 | 0.83 | HPGD (0.56) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| SCHEMBL5536717 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TSHRHSD17B10USP2ADRB1 | |
| Hydrochloric Acid SCHEMBL31490556 | 0.82 | ADRB1 (0.51) | ALDH1A1TSHRHSD17B10USP2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2025-04-08 | — | — | US | disclosed |
| CN-119698414-A | Indole-phenyl piperidine compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998041527-A1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LIMITED (JP) | 1998-09-24 | — | — | WO | disclosed |
| WO-1998000144-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000401-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0749967-A1 | Substituted benzothiazine derivative | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0749971-A1 | Thiopyran derivatives | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
| CN-1119859-A | benzothiazine derivatives | SUNTORY LTD (JP) | 1996-04-03 | — | — | CN | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | ALDH1A1 1304/4885TSHR 1810/4885HSD17B10 1049/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | ALDH1A1 1900/4885TSHR 4554/4885HSD17B10 3461/4885 |
| US-12269814-B2 | Process for preparing a compound useful to treat mycoses | C1R, CBR1, CBR3 | ALDH1A1 3385/4885TSHR 533/4885HSD17B10 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.